15 research outputs found
Pre-Interventional Kynurenine Predicts Medium-Term Outcome after Contrast Media Exposure Due to Coronary Angiography
Background/Aims: Contrast induced acute kidney injury (CI-AKI) remains a
serious complication of contrast media enhanced procedures like coronary
angiography. There is still a lack of established biomarkers that help to
identify patients at high risk for short and long-term complications. The aim
of the current study was to evaluate plasma kynurenine as a predictive
biomarker for CI-AKI and long-term complications, measured by the combined
endpoint "major adverse kidney events" (MAKE) up to 120 days after CM
application. Methods: In this prospective cohort study 245 patients undergoing
coronary angiography were analyzed. Blood samples were obtained at baseline,
24h and 48h after contrast media (CM) application to diagnose CI-AKI. Patients
were followed for 120 days for adverse clinical events including death, the
need for dialysis, and a doubling of plasma creatinine. Occurrence of any of
these events was summarized in the combined endpoint MAKE. Results:
Preinterventional plasma kynurenine was not associated with CI-AKI. Patients
who later developed MAKE displayed significantly increased preinterventional
plasma kynurenine levels (p<0.0001). ROC analysis revealed that
preinterventional kynurenine is highly predictive for MAKE (AUC=0.838;
p<0.0001). The optimal cutoff was found at ≥3.5 µmol/L Using this cutoff, the
Kaplan-Meier estimator demonstrated that concentrations of plasma kynurenine
≥3.5 µmol/L were significantly associated with a higher prevalence of MAKE
until follow up (p<0.0001). This association remained significant in
multivariate Cox regression models adjusted for relevant factors of long-term
renal outcome. Conclusion: Preinterventional plasma kynurenine might serve as
a highly predictive biomarker for MAKE up to 120 days after coronary
angiography
Urinary Vitamin D Binding Protein and KIM-1 Are Potent New Biomarkers of Major Adverse Renal Events in Patients Undergoing Coronary Angiography
Background Vitamin-D-binding protein (VDBP) is a low molecular weight protein
that is filtered through the glomerulus as a 25-(OH) vitamin D 3/VDBP complex.
In the normal kidney VDBP is reabsorbed and catabolized by proximal tubule
epithelial cells reducing the urinary excretion to trace amounts. Acute
tubular injury is expected to result in urinary VDBP loss. The purpose of our
study was to explore the potential role of urinary VDBP as a biomarker of an
acute renal damage. Method We included 314 patients with diabetes mellitus or
mild renal impairment undergoing coronary angiography and collected blood and
urine before and 24 hours after the CM application. Patients were followed for
90 days for the composite endpoint major adverse renal events (MARE: need for
dialysis, doubling of serum creatinine after 90 days, unplanned emergency
rehospitalization or death). Results Increased urine VDBP concentration 24
hours after contrast media exposure was predictive for dialysis need (no
dialysis: 113.06 ± 299.61ng/ml, n = 303; need for dialysis: 613.07 ± 700.45
ng/ml, n = 11, Mean ± SD, p<0.001), death (no death during follow-up: 121.41 ±
324.45 ng/ml, n = 306; death during follow-up: 522.01 ± 521.86 ng/ml, n = 8;
Mean ± SD, p<0.003) and MARE (no MARE: 112.08 ± 302.00ng/ml, n = 298; MARE:
506.16 ± 624.61 ng/ml, n = 16, Mean ± SD, p<0.001) during the follow-up of 90
days after contrast media exposure. Correction of urine VDBP concentrations
for creatinine excretion confirmed its predictive value and was consistent
with increased levels of urinary Kidney Injury Molecule-1 (KIM-1) and baseline
plasma creatinine in patients with above mentioned complications. The impact
of urinary VDBP and KIM-1 on MARE was independent of known CIN risk factors
such as anemia, preexisting renal failure, preexisting heart failure, and
diabetes. Conclusions Urinary VDBP is a promising novel biomarker of major
contrast induced nephropathy-associated events 90 days after contrast media
exposure
a prospective clinical trial
Hintergrund: Kontrastmittelgestützte Untersuchungsverfahren finden in
steigender Zahl Anwendung. Kontrastmittelinduziertes Nierenversagen (CIN) ist
dabei eine unerwünschte Wirkung. Risikofaktoren hierfür sind, z.B. hohes
Alter, Diabetes mellitus, Herz- oder Niereninsuffizienz. Diese Risiken nehmen
aufgrund des demographischen Wandels zu. Die CIN ist mit einem schlechteren
Kurz- und Langzeit-Outcome der betroffenen Patienten verbunden. Die gängige
Definition der CIN basiert auf der Messung des Serum-Kreatinin, durch die das
Nierenversagen jedoch erst 24-72h nach Kontrastmittelgabe angezeigt wird.
Angesichts der sehr kurzen mittleren Krankenhausverweildauer von Patienten,
stellt sich die Frage nach einem Biomarker, der eine CIN früher
diagnostiziert. S100a12 und Calprotectin sind S100-Proteine, die in hoher
Konzentration in aktivierten Granulozyten vorkommen, aber auch im Gewebe
induzierbar sind. Sie gehören zu den „Damage-associated molecular pattern
proteins“ (DAMP). Intrazellulär erfüllen sie Aufgaben der Zellhomöostase. Bei
einem Zellschaden werden sie jedoch frei und verursachen die Aktivierung und
Aufrechterhaltung einer Immunantwort. Ziel dieser Arbeit ist, Calprotectin und
S100a12 im Urin als Biomarker für eine CIN zu untersuchen. Zusätzlich wird ein
Zusammenhang mit dem Outcome der Patienten drei Monate nach Kontrastmittelgabe
anhand sekundärer Endpunkte betrachtet. Methode: Basis dieser Arbeit ist eine
prospektive Studie an 314 Patienten mit erhöhtem Risiko für eine CIN. Alle
Patienten erhielten eine elektive Herzkatheteruntersuchung. Aus Urinproben vor
und 24h nach KM wurde S100a12 und Calprotectin bestimmt. Gleichzeitig erfolgte
eine Serum-Kreatininmessung. Zusätzlich wurde Kreatinin nach 48h bestimmt.
Drei Monate nach Kontrastmittelgabe wurden die Probanden in einer Follow-up-
Untersuchung auf die Endpunkte: „Verdopplung des Serumkreatinins“, „Dialyse“,
„weitere Krankenhausaufenthalte“ und „Tod“ hin untersucht und erhielten eine
weitere Serum-Kreatininmessung. Ergebnisse: 21 (7,4%) von 283 Patienten der
Studienkohorte erlitten eine CIN. Die Analyse der Biomarker zeigte, dass CIN-
Patienten 24h nach Kontrastmittelgabe signifikant höhere S100a12-Werte haben,
als Patienten ohne CIN. Bei der Auswertung hinsichtlich der Calprotectin-
Konzentration ergaben sich bei Patienten mit CIN nicht signifikant höhere
Konzentrationen vor und 24h nach Kontrastmittelgabe. Patienten, die zum
Zeitpunkt der Follow-up-Untersuchung einen Endpunkt erreicht hatten, wiesen
jeweils vor und 24h nach Kontrastmittelgabe höhere S100a12- und Calprotectin-
Konzentrationen auf, als Patienten, die keinen der beschriebenen Endpunkte
erreichten. Dies erwies sich jedoch als nicht signifikant. Ein weiteres
Ergebnis ist ein hoch signifikanter Unterschied der S100a12- und Calprotectin-
Konzentrationen vor und 24h nach KM in Abhängigkeit vom Geschlecht. Die
weiblichen Patienten wiesen hierbei höhere Werte auf als die männlichen.
Schlussfolgerung: S100a12 eignet sich potentiell als Biomarker für die
Diagnostik der CIN. Calprotectin erscheint in diesem Zusammenhang ungeeignet.
Es sollten ergänzende Studien durchgeführt werden, um dies zu bestätigen. Im
Bezug auf das Outcome der Patienten anhand der sekundären Endpunkte ergaben
sich für S100a12 und Calprotectin keine signifikanten Ergebnisse.Background: There are a rising number of patients undergoing radiocontrast
media-enhanced examinations. Contrast media-induced kidney injury (CIN) is a
side effect of the radiocontrast agent. Due to demographic changes, the
incidence of risk factors for CIN-, such as advanced age, diabetes mellitus
and cardiac or renal failure will increase. CIN is associated with worse
short-and long-term outcomes. Today's common definition of CIN is based on
measurement of the serum creatinine, which only indicates renal failure
24-72hrs after administration of radiocontrast media. It is necessary to find
an earlier biomarker to indicate CIN. S100a12 and calprotectin are proteins
that occur in high concentrations in activated granulocytes and can be induced
in tissue. They belong to the "Damage-associated molecular pattern proteins"
(DAMP) and fulfill the duties of intracellular homeostasis. During tissue or
cell damage they are responsible for the activation and amplification of an
immune response. The goal of this paper is to examine calprotectin and S100a12
in urine as a biomarker for CIN. Additionally, calprotectin and S100a12 are
analyzed regarding the outcome based on specific endpoints three months after
the administration of the contrast medium. Methods: We performed a prospective
study on 314 patients with an increased risk for CIN undergoing percutaneous
coronary angiography. Urine samples before and 24h after contrast media
application were collected. S100a12 and calprotectin were measured. At the
same time, creatinine samples were taken from the blood. Three months after
administration of the contrast medium, data regarding the endpoints: "doubling
of serum creatinine", "dialysis", "non-elective hospitalizations" and "death"
were collected and another blood sample for creatinine measurement taken.
Results: 21 (7,4%) out of 283 patients developed CIN. The results show that
patients who developed CIN had significantly higher S100a12-levels than
patients without CIN, 24hrs after administration of contrast medium. The
calprotectin-level was not significantly higher before and 24hrs after
contrast administration in patients with CIN. The patients who reached an
endpoint, had higher S100a12- and calprotectin-levels before and 24hrs after
contrast administration, compared to patients who did not reach an endpoint.
However, this difference proved to be statistically insignificant. There is
also strong evidence for a gender-dependent difference of S100a12- and
calprotectin-levels before and 24hrs after contrast administration, with women
having higher levels. Conclusion: S100a12 has the potential to be a promising
biomarker detecting CIN. Calprotectin is as a biomarker rather unsuitable in
this context. It is necessary to carry out further studies to confirm this. In
terms of patient outcome on the basis of secondary endpoints no significant
results for S100A12 and calprotectin were found
Urinary ET-1 excretion after exposure to radio-contrast media in diabetic patient and patients with preexisting impaired renal function
Pre-Interventional Kynurenine Predicts Medium-Term Outcome after Contrast Media Exposure Due to Coronary Angiography
Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast medium.
The use of iodine-based contrast agents entails the risk of contrast induced nephropathy (CIN). Radiocontrast agents elicit the third most common cause of nephropathy among hospitalized patients, accounting for 11-12% of cases. CIN is connected with clinically significant consequences, including increased morbidity, prolonged hospitalization, increased risk of complications, potential need for dialysis, and increased mortality rate. The number of in-hospital examinations using iodine-based contrast media has been significantly increasing over the last decade. In order to protect patients from possible complications of such examinations, new biomarkers are needed that are able to predict a risk of contrast-induced nephropathy. Urinary and plasma cyclic guanosine monophosphate (cGMP) concentrations are influenced by renal function. Urinary cGMP is primarily of renal cellular origin. Therefore, we assessed if urinary cGMP concentration may predict major adverse renal events (MARE) after contrast media exposure during coronary angiography.Urine samples were prospectively collected from non-randomized consecutive patients with either diabetes or preexisting impaired kidney function receiving intra-arterial contrast medium (CM) for emergent or elective coronary angiography at the Charité Campus Mitte, University Hospital Berlin. Urinary cGMP concentration in spot urine was analyzed 24 hours after CM exposure. Patients were followed up over 90 days for occurrence of death, initiation of dialysis, doubling of plasma creatinine concentration or MARE.In total, 289 consecutive patients were included into the study. Urine cGMP/creatinine ratio 24 hours before CM exposure expressed as mean±SD was predictive for the need of dialysis (no dialysis: 89.77±92.85 μM/mM, n = 277; need for dialysis: 140.3±82.90 μM/mM, n = 12, p = 0.008), death (no death during follow-up: 90.60±92.50 μM/mM, n = 280; death during follow-up: 169.88±81.52 μM/mM, n = 9; p = 0.002), and the composite endpoint MARE (no MARE: 86.02±93.17 μM/mM, n = 271; MARE: 146.64±74.68 μM/mM, n = 18, p<0.001) during the follow-up of 90 days after contrast media application. cGMP/creatinine ratio stayed significantly increased at values exceeding 120 μM/mM in patients who developed MARE, required dialysis or died.Urinary cGMP/creatinine ratio ≥ 120 μM/mM before CM exposure is a promising biomarker for the need of dialysis and all-cause mortality 90 days after CM exposure in patients with preexisting renal impairment or diabetes
Model of megalin function in renal uptake and activation of 25-(OH) Vitamin D3. [11]
<p>Model of megalin function in renal uptake and activation of 25-(OH) Vitamin D3. [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0145723#pone.0145723.ref011" target="_blank">11</a>]</p
Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast medium - Fig 3
<p><b>Distribution of urinary cGMP/creatinine ratios (μM/mM) before 24 hours after and 48h after contrast media application detected in patients without (No) or with (Yes) following adverse events: death(a), dialysis (b) or MARE (c).</b><i>cGMP</i>: <i>urinary cyclic guanosine monophosphate</i>, <i>MARE</i>: <i>major adverse renal event</i>, <i>*** p<0</i>.<i>001</i>, <i>** p<0</i>.<i>01</i>, <i>* p<0</i>.<i>05</i>.</p
Multivariate logistic regression analysis for predictors of MARE.
<p>Multivariate logistic regression analysis for predictors of MARE.</p